FindTrial
Sign In

A trial to compare conventional drug therapy versus conventional drug therapy along with Pulmonary Rehabilitation in patients with Interstitial Lung Disease.

Comparison of conventional drug therapy alone versus conventional drug therapy along with structured 12 -weeks home-based pulmonary rehabilitation program on patients with Interstitial Lung Diseases in a tertiary care centreâ?? A stratified Randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047192
Enrollment
68
Registered
2022-11-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J848- Other specified interstitial pulmonary diseases

Interventions

Intervention1: Conventional Drug Therapy along with Pulmonary rehabilitation: The intervention group i.e., Pulmonary Rehabilitation comprises four parts: Exercise education, Strength training, Nutriti

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age above 18 years ILD of any types (Idiopathic Interstitial Pneumonia, Autoimmune ILD, Sarcoidosis, other ILDs)

Exclusion criteria

Exclusion criteria: 1. Other conditions which are contraindications for spirometry, according to American Thoracic Society guidelines. 2.Thoracic surgery in the previous six months or Patient with previous hospitalization in the last 3 weeks. 2. Patient not willing to do PR 3.Orthopaedic conditions which interfere with walking

Design outcomes

Primary

MeasureTime frame
To study the effect of conventional drug therapy along with a home-based, 12 -week pulmonary rehabilitation program on 6MWT performance capacity of ILD patients when compared to conventional drug therapy alone.Timepoint: 12 weeks—

Secondary

MeasureTime frame
To study the effect of home-based, Pulmonary Rehabilitation on â?¢ Pulmonary function, assessed by Spirometry â?¢ Breathlessness, assessed by mMRC Dyspnoea Scale â?¢ Respiratory function, assessed by St George Respiratory Questionnaire Timepoint: 12 weeks—

Countries

India

Contacts

Public ContactChristie George Joseph

JIPMER

mail2manju22@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026